Glycosmedia

Diabetes News Service

Privacy & Cookies: This site uses cookies. By continuing to use this website, you agree to their use.
To find out more, including how to control cookies, see here: Cookies Policy
  • News
  • Archive
  • Categories & Tags
  • Journal Watch
  • Updates
  • Education
  • Reviews
  • About us ▼
    • About Glycosmedia
    • Editorial Team
    • Frequently asked questions
    • Comments
    • Press Releases
    • Disclaimer
  • Subscribe
  • Contact

Diabetes News June 26th 2009

June 26th 2009

Quality of healthcare in England, Wales, Scotland, Northern Ireland: an intra-UK chartbook
This chartbook brings together publicly available data from across the four home nations of the UK and presents an intra-UK picture of quality. 126-page PDF (The Health Foundation via NHS Evidence)

ONGLYZA™ (Saxagliptin) Receives Positive Opinion in Europe for the Treatment of Type 2 Diabetes
Bristol-Myers Squibb Company and AstraZeneca today announced that their marketing authorization application for ONGLYZA (saxagliptin) received a positive opinion from the Committee for Medicinal Products for Human Use (CHMP) for the treatment of type 2 diabetes in adults as add-on therapy with metformin, a thiazolidinedione or a sulphonylurea (Business Wire)

MannKind Closes Acquisition of Insulin Assets from Pfizer
MannKind Corporation today announced that it has completed its acquisition fromPfizer Inc. of a quantity of bulk insulin and a license to manufacture bulk insulin for use in pulmonary delivery pursuant to an insulin sale and purchase agreement (PharmaLive)

Putting feet first
Commissioning specialist services for the management and prevention of diabetic foot disease in hospitals (NHS)

The establishment of a new national network leads to quality improvement in childhood diabetes: Implementation of the ISPAD Guidelines
During the establishment of a system for benchmarking of diabetes treatment in Norway the outcomes showed significant improvements associated with changes in management and the quality of screening assessments (Pediatric Diabetes)

Diabetes diagnostics set to grow
The European diabetes diagnostics market is on the verge of a huge expansion with segments such as self monitoring tests offering room for extreme growth, analysts have found (eHealth Europe)

Home Diagnostics Launches TRUEmanager Diabetes Management Software
The software allows patients to easily download blood glucose testing results from their meter directly onto a home computer (Business Wire)

Major Study Highlights Weight Differences Among 3-19 Year-olds With Type 1 And 2 Diabetes
A major study of three to 19 year-olds has provided vital data on the weight problems faced by the growing number of children and young people with type 1 diabetes, which is more prevalent in younger age groups than type 2 diabetes (NHS Diabetes)

Glycemic exposure is affected favorably by inhaled human insulin (Exubera) as compared with subcutaneous insulin glargine (Lantus) in patients with type 2 diabetes
Prandial insulin therapy with Exubera , using a higher daily insulin dose, reduces total daily glucose exposure – in particular postmeal glycemia – more effectively than a basal insulin analog (PubMed)

MacroGenics and Lilly Achieve Targeted Patient Enrollment in PROTEGE
A Global Phase 2/3 Clinical Trial of Teplizumab in Type 1 Diabetes (PharmaLive)

Prescribing for diabetes in England : an analysis of volume, expenditure and trends
This report from the Yorkshire and Humber Public Health Observatory provides an overview of prescribing for diabetes in England. 28-page PDF (YHPHO)

Living with Plenty – meeting the challenge of diabetes
The twenty first century role of pharmacy and pharmaceutical innovation in the prevention and treatment of diabetes mellitus. 36-page PDF (The School of Pharmacy, University of London)

Is the current therapeutic armamentarium in diabetes enough to control the epidemic and its consequences?
Currently available oral drugs do not address the key driver of type 2 diabetes—loss of functional beta-cell mass. In the future, new oral treatments must improve this, whilst providing durable blood glucose control and long-term tolerability (Acta Diabetologica)

President Obama urged to combat obesity
U.S. physicians, health organizations and nutrition experts are asking President Barack Obama to create a Presidential Commission to combat obesity (Diabetes Today)

‘Patchy’ diabetes services worry
Only 2% of diabetics are attending classes set up to help manage their condition, according to research for the BBC’s Eye on Wales programme (BBC, UK)

Is Diabetes Mellitus an Independent Risk Factor for Venous Thromboembolism? A Population-Based Case–Control Study
Diabetes mellitus and diabetes complications are not independent risk factors for incident VTE (Arteriosclerosis, Thrombosis, and Vascular Biology)

CV events improved with aleglitazar in patients with type 2 diabetes
Patients with type 2 diabetes experienced a favorable balance in the safety and efficacy of dual peroxisome proliferator-activated receptor-alpha/gamma agonist aleglitazar and risk for cardiovascular events, according to short-term, phase-2 data (Endocrine Today)

Effects of a Higher-Carbohydrate/Lower-Fat Diet Versus a Lower-Carbohydrate/Higher-Fat-Monounsaturated Diet on Postmeal Triglyceride Concentrations and other Cardiovascular Risk Factors in Type 1 Diabetes
A lower-carbohydrate/higher-fat-monounsaturated diet in type 1 diabetes could offer an appropriate choice for non-obese subjects in good metabolic and weight control (Diabetes Care)

Diabetic muscle infarction
Diabetic muscle infarction is a rare complication of diabetes that occurs in patients with type 1 diabetes (70% of total cases) or in patients with poorly controlled type 2 diabetes (BMJ, UK)

A review of insulin and insulin regimens in type 2 diabetes
The insulin groups discussed include the Basal insulins, the bolus or prandial insulins, and the premixed insulins. Furthermore, an approach to the designing of an insulin regimen is discussed, and comments made on how to further intensify therapy depending on the response experienced. 6-page PDF (South African Family Practice)

First children vaccinated in Diamyd®-study in order to prevent diabetes
The purpose of the study is to investigate whether vaccination with Diamyd® may prevent or delay that children, with high risk to develop type 1 diabetes, get the disease. This is the first time ever that vaccination is tested with the purpose to prevent this chronic disease. PDF (Diamyd Medical)

Walgreens to test diabetes care model
Ramping up its increasingly aggressive commitment to being a broad-based health solutions company, Walgreens is gearing up to test a new, pharmacy-centered disease management program for patients with diabetes (Drug Store News)

International Expert Committee Report on the Role of the A1C Assay in the Diagnosis of Diabetes
The International Expert Committee hopes that its report will serve as a stimulus to the international community and professional organizations to consider the use of the A1C assay for the diagnosis of diabetes (Diabetes Care)

2009 Annual Evidence Update – Obesity
Childhood obesity: surveillance and prevention (NHS Evidence)

HIV infection alone does not increase risk of diabetes
people with HIV had a lower risk of diabetes than HIV-negative individuals (Aidsmap)

New theory for global diabetes epidemic
A new “fertility first” hypothesis published this week by a group of international experts in the American Journal of Human Biology, proposes that the global epidemic of Type 2 diabetes has its origins in the struggle, over millennia, to sustain human fertility in environments defined by famine (University of Sydney)

Diabetes and acute coronary syndromes
Despite the benefit, multiple surveys have demonstrated that, in the setting of ACS, diabetic patients receive evidence-based therapy less frequently than non-diabetic counterparts (Best Practice & Research Clinical Endocrinology & Metabolism)

Impact of Glycemic Treatment Choices on Cardiovascular Complications in Type 2 Diabetes
Although past epidemiological studies have shown a relationship between glycated hemoglobin levels and CV events in patients with type 2 diabetes, recent large randomized clinical trials (ACCORD, ADVANCE, and VADT) lasting 3.5 to 5.6 years have found that intensive glycemic control either has no impact on CV outcomes or even worsens them (Cardiology in Review)

Access Pharmaceuticals Announces Initiation of Two New Cobalamin™ Oral Insulin Drug Delivery Collaborations
Cobalamin oral insulin and oral human growth hormone formulations provide significant pharmacological responses (Access Pharmaceuticals)

Research by Hebrew University scientist holds promise for novel oral anti-diabetic drugs
Promise is held out for the development of novel oral drugs to control blood glucose levels in diabetes patients as the result of research by a scientist at the (Hebrew University of Jerusalem)

Melatonin receptors in pancreatic islets: good morning to a novel type 2 diabetes gene
Individuals may be more sensitive to the actions of melatonin, leading to impaired insulin secretion. Blocking the inhibition of insulin secretion by melatonin may be a novel therapeutic avenue for type 2 diabetes (Diabetologia)

Categories: News Pre-2012

Subscribe

subscribe-iconFREE weekly updates by email Please CLICK HERE

Platinum Sponsors

Boehringer Ingelheim Lilly

Gold Sponsors

Napp DiabetesNovo NordiskAstraZeneca

Silver Sponsors

Abbott Diabetes CareAbout Ascensia Diabetes CareWelsh Endocrinology and Diabetes Society (WEDS)

FUNDING NOTICE

The Glycosmedia website and newsletter has been made possible with funding support from our sponsors. None of our sponsors have control over the content of the website, newsletter, apps, Twitter feed or RSS newsfeed.

For information about sponsorship and advertising please contact our editor-in-chief Jim Young jim@glycosmedia.com

Advertisers

CRC Press

The organisations advertising in this section do not have any input into, or editorial control over the content of this website.

Join us on Facebook

Join us on Facebook

Please share Glycosmedia:

Follow us on Twitter

My Tweets

mobileGlycosmedia is also available as an App:

For iPhone and iPad | For Android devices


Sponsorship and Advertising

For information about sponsorship and advertising please contact our editor-in-chief Jim Young jim@glycosmedia.com

Copyright © 2021 Glycosmedia Partnership